April 17, 2024 |
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

The study, led by Johnson and Johnson, explored using real world evidence collected by patient records from physicians to examine the impact of genetic mutations on response to therapy in urothelial carcinoma.
The paper is titled ‘Prognostic Value of Fibroblast Growth Factor Receptor Genetic Alterations in Metastatic Urothelial Carcinoma’ and was published in Clinical Genitourinary Cancer. It explores the impact of FGFR mutations on response to different first-line anti-tumor regimens treating locally advanced or metastatic urothelial carcinoma. A total of 104 physicians treating first-line locally advanced or metastatic patients with systemic therapy contributed a total of 414 eligible patient records for the real-world evidence study. Findings showed that although FGFR mutations did not impact the overall progression free survival relative to wild type FGFR patients, the subset of gene mutation patients who received first-line immune checkpoint inhibitors without chemotherapy had significantly higher rates of progression relative to wild type patients receiving immune checkpoint inhibitors without chemotherapy.
For this project, Research Partnership was responsible for the survey design, enrolling respondents via fieldwork partners, performing analysis, both internally and with an external statistical analysis partner, as well as reading and approving drafts of the manuscript. We were privileged to assist our partners as they work to better understand responses to anti-tumor therapy in this malignancy and help oncologists refine the optimal treatment for patients.
This content was provided by Inizio
Latest Content from Inizio
The best performing privately-owned UK pharmaceutical businesses were revealed earlier this month with the publication of Pharma Times’ Alantra Pharma Fast 50 annual report.Read more about this report here
Last month Analytics Director Misti Paul attended the Data Analytics & Insight Conference. In our latest blog post she reflects on the presentations that were given and what lessons can be…
US Director Liza Pliss recently presented the paper ‘Optimize your digital assets with UX research’ at the PMR Conference in New Jersey, USA. Don’t worry if you missed it though,…
We have published new Living with Rheumatoid Arthritis reports in 5EU, Japan and Canada. The reports consist of 30-minute quantitative online and qualitative telephone interviews with RA patients. Read more on…
An overview of the RA biologic patientOur RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at…
In partnership with pharmaphorumView the webcast »The emergence of low-cost biosimilar versions of Humira and the new janus kinase (JAK) inhibitors, are shaking up a once-stable market.Although there are only…
Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
Five new recruits support further growth of the Pharma & Life Sciences team
In the first part of our series covering market research innovations which have value in healthcare, we demonstrate how we’ve been using facial analysis to delve further into respondents’ reactions…
Research Partnership launches new patient Living with  Rheumatoid Arthritis (EU & Japan)  2019 report.r Living with Rheumatoid Arthritis (RA) is a quantitative study conducted online amongst 390 patients diagnosed with RA in…
